Figure 1
From: The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update
The AFREZZA® (MannKind Corporation, Valencia, CA, USA): a second generation device for delivering dry powder insulin. It is a drug-device combination product, consisting of AFREZZA inhalation powder pre-metered into single use dose cartridges and a lightweight, AFREZZA inhaler. Insulin is placed into the chamber in an aspirin-like tablet. Closing the device crushes it into a fine powder which is then inhaled by the patient (downloaded from MannKind website at http://www.mannkindcorp.com/product-pipeline-diabetes-afrezza.htm).